7. The method of Claim 6, wherein the single vector comprises at least one internal ribosomal entry site.

8. The method of Claim 6, wherein the single vector comprises, in order, a first promoter, *OCT4*, IRES2, *SOX2*, a second promoter, *SV40 T* antigen, IRES2, and *KLF4*.

9. The method of Claim 6, wherein the vector comprises, in order, a first promoter, *OCT4*, IRES2, *SOX2*, a second promoter, *c-Myc*, IRES 2, *KLF4*, a third promoter, *NANOG*, IRES2, and *LIN28*.

10. The method of Claim 1, wherein a first non-viral episomal vector comprises, in order, a first promoter, *OCT4*, IRES2, *SOX2*, a second promoter, *SV40 T* antigen, IRES2, and *KLF4*, wherein a second vector comprises, in order, a third promoter, *OCT4*, IRES2, *SOX2*, a fourth promoter, *NANOG*, IRES2, and *KLF4*, and wherein a third vector comprises, in order, a fifth promoter, *c-Myc*, IRES 2, and *LN28*, wherein the promoters need not be identical.

11. The method of Claim 10, wherein each of the first, second, third, and fourth promoters is an elongation factor lα (EFlα) gene promoter.

12. The method of Claim 1 ~~5~~, wherein a first non-viral episomal vector comprises, in order, a first promoter, *OCT4*, IRES2, *SOX2*, a second promoter, *KLF4*, IRES2, *c-Myc*, a third promoter, *NANOG*, IRES2, and *LN28*, wherein a second vector comprises, in order, a fourth promoter, *OCT4*, IRES2, *SOX2*, a fifth promoter, *SV40 T* antigen, IRES2, and *KLF4*, wherein the promoters need not be identical.

13. The method of Claim 12, wherein each of the first, third, fourth, and fifth promoters is an EFlα gene promoter and wherein the second promoter is a cytomegalovirus immediate early gene (CMV) promoter.

14. The method of Claim 1, wherein a first non-viral episomal vector comprises, in order, a first promoter, *OCT4*, IRES2, *SOX2*, a second promoter, *NANOG*, IRES2, and *LIN28*, wherein a second vector comprises, in order, a third promoter, *OCT4*, IRES2, *SOX2*, a fourth promoter, *SV40 T* antigen, IRES2, and *KLF4*, and wherein a third vector comprises, in order, a fifth promoter, *OCT4*, IRES2, *SOX2*, a sixth promoter, *c-Myc*, IRES 2, and *KLF4*, wherein the promoters need not be identical.

15. An enriched population of primate induced pluripotent cells substantially genetically identical to a post-natal individual and substantially free of any vector component associated with induction of pluripotency, wherein the primate induced pluripotent cells express pluripotent cell-specific markers, have a cell morphology characteristic of undifferentiated cells, and can differentiate into cells of all three germ layers.